Scholar Rock Holding Corporatio (SRRK) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $45.37: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10 and A.R:R 1.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 16%; Below-average business quality; Negative price momentum.
Scholar Rock is a pre-commercial biopharma developing apitegromab, an anti-myostatin antibody, as potential first muscle-targeted therapy for SMA; Phase 3 SAPPHIRE was positive but BLA received a CRL in September 2025 due to third-party fill-finish facility GMP issues. Pipeline... Read more
Sell if holding. Engine safety override at $45.37: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10 and A.R:R 1.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 16%; Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.5/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 58d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: moderate.
Recent developments
updated 2026-06-09Recent Developments — Scholar Rock Holding Corporatio
Latest news
- NEWS Barclays Maintains Overweight on Scholar Rock Holding, Raises Price Target to $55 — benzinga May 8, 2026 positive
- NEWS HC Wainwright & Co. Maintains Buy on Scholar Rock Holding, Raises Price Target to $65 — benzinga May 8, 2026 positive
- NEWS Scholar Rock Holding Q1 EPS $(0.83), Inline — benzinga May 7, 2026 neutral
- NEWS Canaccord Genuity Initiates Coverage On Scholar Rock Holding with Buy Rating, Announces Price Target of $62 — benzinga Apr 21, 2026 positive
Generated 2026-06-15T18:11:47Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineapitegromab (SMA)10-K Item 1: 'Commercialize apitegromab for children and adults living with SMA. We are developing our first product candidate, apitegromab, for the treatment of patients with SMA.'
- HIGHSupplierthird-party fill-finish facility10-K Item 1A: 'In September 2025, we received a CRL from the FDA citing observations identified during an FDA inspection of a third-party fill-finish facility.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $45.37: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10 and A.R:R 1.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 16%; Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $42.39. Score 4.5/10, moderate confidence.
Take-profit target: $53.38 (+17.1% upside). Prior stop was $42.39. Stop-loss: $42.39.
Concentration risk — Pipeline: apitegromab (SMA); Concentration risk — Supplier: third-party fill-finish facility; Quality below floor (1.5 < 4.0).
Scholar Rock Holding Corporatio trades at a P/E of N/A (forward -18.5). TrendMatrix value score: 7.5/10. Verdict: Sell.
24 analysts cover SRRK with a consensus score of 4.3/5. Average price target: $59.
What does Scholar Rock Holding Corporatio do?Scholar Rock is a pre-commercial biopharma developing apitegromab, an anti-myostatin antibody, as potential first...
Scholar Rock is a pre-commercial biopharma developing apitegromab, an anti-myostatin antibody, as potential first muscle-targeted therapy for SMA; Phase 3 SAPPHIRE was positive but BLA received a CRL in September 2025 due to third-party fill-finish facility GMP issues. Pipeline also includes SRK-439 (Phase 1) and STK-002-class programs.